Insider Trading May 1, 2026 04:32 PM

Vita Coco Executive Chairman Executes $3.4 Million Stock Sale Amid Robust Fiscal Performance

Michael Kirban disposes of 50,000 shares via Rule 10b5-1 plan as the company reports significant revenue and earnings beats.

By Sofia Navarro COCO
Vita Coco Executive Chairman Executes $3.4 Million Stock Sale Amid Robust Fiscal Performance
COCO

Michael Kirban, the Executive Chairman of Vita Coco Company, Inc. (NASDAQ:COCO), has completed a sale of common stock totaling $3.4 million. The transaction, which involved 50,000 shares, took place on April 30, 2026, at a price point of $68.00 per share. This divestment was carried out in accordance with a Rule 10b5-1 trading plan.The sale occurs during a period of significant stock appreciation for the company; COCO has seen a 97% return over the last year and is currently trading near its 52-week high of $69.58. The company maintains a market capitalization of $3.77 billion.

Key Points

  • <li><strong>Strong Financial Momentum:</strong> Vita Coco reported significant growth in Q1 fiscal 2026, with revenue increasing 37% year-over-year to $180 million and net income exceeding analyst expectations. This impacts the consumer goods sector by demonstrating high demand and operational efficiency.</li>
  • <li><strong>Insider Liquidity via Pre-set Plans:</strong> The sale of $3.4 million in stock by Executive Chairman Michael Kirban was conducted through a Rule 10b5-1 plan, providing liquidity while the stock trades near its 52-week high. This reflects how executive compensation and liquidity needs are managed within the broader equity markets.</li>
  • <li><strong>Positive Analyst Sentiment:</strong> Major institutions including BofA Securities and Evercore ISI have raised price targets following strong earnings, signaling optimism in the company's growth trajectory within the beverage industry.</li>

Executive Transaction Details

On April 30, 2026, Vita Coco Company, Inc. Executive Chairman Michael Kirban sold 50,000 shares of the company's common stock. The transaction was priced at $68.00 per share, resulting in a total sale value of $3,400,000. According to regulatory filings, these sales were executed under the framework of a Rule 10b5-1 trading plan.

Following this specific transaction, Mr. Kirban's holdings remain substantial through various vehicles. He holds 143,799 shares directly. Additionally, he maintains indirect ownership of 515,681 shares through the Michael Kirban Revocable Trust and another 1,479,049 shares via the Michael Kirban 2010 Trust.

The filings also outlined Mr. Kirban's derivative positions. These include non-qualified stock options to purchase Vita Coco common stock. Specifically, there are fully vested options for 546,000 shares and another tranche of 40,950 shares, both of which carry an exercise price of $10.178 per share. Furthermore, he holds options for a total of 663,973 shares with exercise prices spanning from $15.00 to $32.78. These options are set to vest in annual installments over various timeframes, with expiration dates reaching as far as March 2035.

Fiscal Performance and Market Reaction

The insider activity follows a period of strong financial results for Vita Coco. For the first quarter of fiscal 2026, the company reported sales of $180 million, which represents a 37% increase compared to the previous year. This revenue figure exceeded the expectations set by both Visible Alpha Consensus and BofA Securities.

Profitability also outpaced forecasts. The company reported net income of $30 million, or $0.50 per diluted share, surpassing the anticipated $0.315 per share. Adjusted EBITDA reached $38.7 million, notably higher than the $26.0 million expected by the Street. In light of these results, several analysts have adjusted their outlooks. BofA Securities maintained a Buy rating and raised its price target to $72, while Evercore ISI issued an Outperform rating and increased its price target to $75.

Valuation Context

Despite the positive momentum in earnings, valuation metrics suggest caution. Analysis from InvestingPro indicates that COCO may be overvalued based on Fair Value assessments, noting that the stock is currently trading at a P/E ratio of 37.38.

Risks

  • <li><strong>Valuation Concerns:</strong> Based on InvestingPro analysis, COCO appears overvalued according to Fair Value assessments, particularly with a P/E ratio of 37.38. This poses a risk to investors in the consumer staples sector if market corrections occur.</li>
  • <li><strong>Stock Price Volatility:</strong> While the stock has delivered a 97% return over the past year and is trading near its 52-week high, any deviation from the current growth trend could impact price stability for shareholders.</li>

More from Insider Trading

Marcus & Millichap Director Executes Substantial Common Stock Purchase May 4, 2026 Patterson-UTI CEO Executes Multi-Million Dollar Stock Sale Amidst Year-to-Date Surge May 4, 2026 Snowflake Director Michael Speiser Executes $7.18 Million in Stock Sales May 4, 2026 Edwards Lifesciences Executive Executes Stock Transactions Amid Recent Financial Growth May 4, 2026 Entrada Therapeutics President and COO Executes Stock Sale via Rule 10b5-1 Plan May 4, 2026